Tuberculosis vaccines are immunological agents that induce protective immunity against tuberculosis caused by the bacterium Mycobacterium tuberculosis. Tuberculosis causes illness in millions of people each year, with millions of new cases and thousands of deaths occurring annually. New and improved vaccines are imperative to control the global TB epidemic.
The global tuberculosis vaccine market is estimated to be valued at US$ 172.42 billion in 2024 and is expected to exhibit a CAGR of 21% over the forecast period of 2024 to 2030.
Despite being a preventable disease, TB remains one of the top 10 causes of death worldwide. Currently, the only available TB vaccine, BCG, provides limited and variable protection, especially in adults. New vaccines with improved efficacy and the ability to curtail the spread of the disease are thus required. This vast unmet need drives the demand for novel vaccines in both developed and emerging nations.
Key Takeaways
Key players operating in the Global Tuberculosis Vaccine Market Size include Fujitsu Limited, Mindtree Limited, IBM Corporation, Wipro Limited, Unisys Corporation, CenturyLink Inc., Virtustream Inc. and HCL Technologies Limited. These companies are actively involved in developing and commercializing new tuberculosis vaccines.
The key opportunities in the market include government funding for research & development of novel vaccines and collaborations between drug makers, technology firms, and research institutes. Nearly USD 1 billion is invested annually towards TB vaccine R&D globally.
Globally, companies are strategizing expansion plans in high burden countries of Africa and Asia to increase geographic footprint and access to target populations. Partnerships with local health authorities can aid last-mile delivery and distribution of affordable vaccines.
Market drivers
- Growing prevalence of drug-resistant TB strains driving demand for improved prevention options
- Heightened government focus and funding for TB control programs worldwide
Market restraints
- High research and development costs associated with new vaccine development
- Lengthy clinical trial and regulatory approval timelines for novel vaccines
The given market overview covers key aspects of the tuberculosis vaccine market like disease overview, need for improved vaccines, current market size and growth projections. The key takeaways section succinctly outlines important parameters like prominent players, growth opportunities and expansion strategies. Market drivers and restraints offer a balanced perspective on factors influencing demand.
Segment Analysis
The tuberculosis vaccine market can be segmented into intradermal vaccines and immungenic vaccines. The intradermal vaccines segment currently dominates the market due to advantages like ease of administration and reduced dosage requirement. This vaccine uses a shorter needle to inject the vaccine into the dermis, which is more efficient in triggering an immune response compared to traditional vaccines administered via intramuscular route.
Global Analysis
North America currently leads the tuberculosis vaccine market due to rising government initiatives for research and development of new and advanced vaccines. The region holds over 30% market share. Asia Pacific is projected to witness the fastest growth during the forecast period owing to high prevalence of tuberculosis and increased awareness. Countries like India, China and Indonesia are promoting vaccination programs which is driving the regional market. Europe currently ranks as the second largest market supported by availability of state-of-the-art healthcare infrastructure.
Get More Insights On This Topic: https://www.ukwebwire.com/tuberculosis-vaccine-market-size-share-analysis-2023-2030/
Comments
0 comment